12964_2016_129_MOESM4_ESM.xlsx (231.67 kB)

Additional file 4: Table S1. of Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells

Download (231.67 kB)
posted on 24.02.2016, 05:00 by Sebastian Halbach, Zehan Hu, Christine Gretzmeier, Julia Ellermann, Franziska Wöhrle, Jörn Dengjel, Tilman Brummer
Anti-GAB2 IP of Imatinib vs DMSO treated cells. Experiment 1 and 2 are averages of two replicates each. SILAC ratios are normalized to GAB2 and log2 transformed. Significant affected proteins are determined using Significance A (MaxQuant, p < 0.05, BH corrected). Proteins are shortlisted if minimally one IP exhibited a significant regulation and the other IP showed the same trend (see Additional file 2: Figure S2). PEP: posterior error probability. (XLSX 231 kb)


José Carreras Leukämie-Stiftung